A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

This study is designed to provide evidence of efficacy of cefiderocol in the treatment of
serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens.

本研究旨在为头孢地尔（cefiderocol）治疗成人耐碳青霉烯类革兰阴性病原菌所致严重感染的疗效提供依据。